title: Ny-ESO-1 expression and immunogenicity associated with transitional cell carcinoma: correlation with tumor grade.
abstract: NY-ESO-1 mRNA expression in transitional cell carcinoma was investigated by reverse transcription-PCR and immunohistochemistry. NY-ESO-1 mRNA was detected in 20 of 62 (32%) tumor specimens. There was a correlation between NY-ESO-1 expression and tumor grade: 0 of 4 (0%) grade 1 (G1), 6 of 26 (23%) grade 2 (G2), and 14 of 32 (44%) grade 3 (G3) tumors were NY-ESO-1 mRNA positive. Immunohistochemical analysis using NY-ESO-1-specific monoclonal antibody ES121 showed that 2 of 14 NY-ESO-1 mRNA-expressing G3 tumors were positive for NY-ESO-1. No NY-ESO-1 staining was observed in the panel of 30 G1 or G2 tumor specimens, including 6 NY-ESO-1 mRNA-positive cases. Sera from an expanded panel of 124 patients with transitional cell carcinoma were tested for the presence of NY-ESO-1 antibody. Seropositivity was observed in 9 of 72 (12.5%) patients with G3 tumors, whereas none of 52 patients with G1 or G2 tumors produced antibody against NY-ESO-1. In the 9 positive patients with NY-ESO-1 antibody, 4 had muscular invasive tumors, and 5 had carcinoma in situ.
authors.affiliation: Department of Urology, Okayama University Medical School, Okayama 700-8558, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Kurashige
authors.forename: Y
authors.initials: Y
authors.lastname: Noguchi
authors.forename: T
authors.initials: T
authors.lastname: Saika
authors.forename: T
authors.initials: T
authors.lastname: Ono
authors.forename: Y
authors.initials: Y
authors.lastname: Nagata
authors.forename: A
authors.initials: A
authors.lastname: Jungbluth
authors.forename: G
authors.initials: G
authors.lastname: Ritter
authors.forename: Y T
authors.initials: YT
authors.lastname: Chen
authors.forename: E
authors.initials: E
authors.lastname: Stockert
authors.forename: T
authors.initials: T
authors.lastname: Tsushima
authors.forename: H
authors.initials: H
authors.lastname: Kumon
authors.forename: L J
authors.initials: LJ
authors.lastname: Old
authors.forename: E
authors.initials: E
authors.lastname: Nakayama
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000912:Antibodies, Neoplasm / Q000096:biosynthesis / Q000097:blood; D000951:Antigens, Neoplasm / Q000096:biosynthesis* / Q000276:immunology; D002295:Carcinoma, Transitional Cell / Q000235:genetics / Q000276:immunology* / Q000473:pathology; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D008565:Membrane Proteins; D008875:Middle Aged; D014176:Protein Biosynthesis; D011506:Proteins / Q000235:genetics / Q000276:immunology; D012333:RNA, Messenger / Q000096:biosynthesis / Q000235:genetics; D014516:Ureteral Neoplasms / Q000235:genetics / Q000276:immunology* / Q000473:pathology; D001749:Urinary Bladder Neoplasms / Q000235:genetics / Q000276:immunology* / Q000473:pathology
chemical_list: D000912:Antibodies, Neoplasm; D000951:Antigens, Neoplasm; C104948:CTAG1B protein, human; D008565:Membrane Proteins; D011506:Proteins; D012333:RNA, Messenger